Funding

submenu

Active research support

Z. Wang - Taking Aim at HBV Eradication Using Novel NRTIs and Capsid Effectors

Z. Wang - Taking Aim at HBV Eradication Using Novel NRTIs and Capsid Effectors

Taking Aim at HBV Eradication Using Novel NRTIs and Capsid Effectors
Grant Number: 5R01AI121315
Duration: 06/14/2016-06/13/2021
Funding Agency: NIAID/National Institute of Health
Type: Multiple PI R01
Principal Investigator(s): Stefan Sarafianos,PhD and Zhengqiang Wang,PhD
Direct cost for ZW: $160,000 / Year
The goal of this grant is to characterize the structural determinants of HIV capsid (CA) core stability, to unravel structural interactions of CA with host factors and to discover CA-targeting antivirals

Z. Wang - Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals

Z. Wang - Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals


Structural studies of HIV Capsid with host factors and Capsid-targeting antivirals
Grant Number: 5R01AI120860
Duration: 06/15/2015—05/31/2020
Funding Agency: NIH/NIAID
Type: Multiple PI R01
Principal Investigator(s): Stefan Sarafianos, PhD and Zhengqiang Wang, PhD
Direct cost for ZW: $100,000 / Year
The goal of this grant is to discover and characterize potent capsid effectors and study their antiviral effect in combination with NRTIs

C. Salomon - New therapeutic strategies for combating biofilm associated pathogens

C. Salomon - New therapeutic strategies for combating biofilm associated pathogens

New therapeutic strategies for combating biofilm associated pathogens
Duration: 10/2014-10/2016
Funding Agency: Center for Drug Design, UMN
Investigator(s):  Christine Salomon, PhD (PI)

R. Geraghty - Identification of Small Molecule Inhibitors of Viral Endonucleases

R. Geraghty - Identification of Small Molecule Inhibitors of Viral Endonucleases

Identification of Small Molecule Inhibitors of Viral Endonucleases
7/1/14 – 6/30/17
Center For Drug Design
Research Development and Seed Grant
Role: PI Robert Geraghty, PhD; Co-Investigator Z. Wang

Z. Wang - Novel Antivirals Targeting the RNase H Activity of HIV Reverse Transcriptase

Z. Wang - Novel Antivirals Targeting the RNase H Activity of HIV Reverse Transcriptase

Novel Antivirals Targeting the RNase H Activity of HIV Reverse Transcriptase
Grant Number: 1R01AI100890
Duration: 07/01/2012—06/30/2017
Funding Agency: NIH/NIAID
Type: Multiple PI R01
Principal Investigator(s): Stefan Sarafianos, PhD; Zhengqiang Wang, PhD
Direct cost for ZW: $148,000 / year

The goal of this grant is to identify and optimize selective inhibitors of HIV RNase H and study detailed biochemistry of different modes of RNase H activities as well as inhibitor binding sites, and eventually validate RNase H as an antiviral target for HIV chemotherapy.